Will open avenues for drug discovery
Scientists have developed a new blood test for Alzheimer’s disease that can detect early indicators of the disease long before the first symptoms appear in patients. The blood test would thus open the door to new avenues in drug discovery, said the researchers from Ruhr University Bochum in Germany.
The blood test uses a technology called immuno-infrared sensor to measure distribution of pathological and healthy structures of amyloid-beta, according to a study published in the Molecular Cell. The pathological amyloid-beta structure is rich in a sticky, sheet-like folding pattern that makes it prone to aggregation, while the healthy structure is not.
The two structures absorb infrared light at a different frequency, allowing the blood test to determine the ratio of healthy to pathological amyloid-beta in the sample.
They found that the test reliably detected amyloid-beta alterations in the blood of participants with mild cognitive impairment that also showed abnormal amyloid deposits in brain scans.